¿ÆÑ§¼Ò·¢ÏÖвßÂÔ£¬ÓÐÍû¡°½â¶³¡±½¥¶³ÈË!
½üÈÕ£¬ÖпÆÔºÉñ¾¿ÆÑ§Ñо¿ËùÐì½ø¿ÎÌâ×éÒÔ¡°ÖØÐ¼¤»îÎÞÒå½éµ¼µÄmRNA½µ½âͨ·¿ÉÓÐЧ¶Ô¿¹C9orf72Ë«ëÄÖØ¸´ÐòÁеÄÉñ¾¶¾ÐÔ¡±ÎªÌ⣬ÔÚÆÚ¿¯Brain£¨IF=10.8£©·¢±íÁËһƪ¹ØÓÚ¼¡Î®Ëõ²àË÷Ó²»¯Ö¢µÄ×îÐÂÑо¿¡£ÔÚÕâÏîÑо¿ÖУ¬°²Åµ»ùÒò³Ðµ£×ªÂ¼×é²âÐò¹¤×÷¡£
¼¡Î®Ëõ²àË÷Ó²»¯Ö¢£¨ALS£©ÊÇÒ»ÖÖÑÏÖØµÄÉñ¾ÍËÐÐÐÔ¼²²¡£¬Ä¿Ç°Ã»ÓÐÓÐЧµÄÖÎÁÆ·½·¨¡£ÔÚÎÒ¹úͨ³£½«¼¡Î®Ëõ²àË÷Ó²»¯Ö¢ÓëÔ˶¯Éñ¾Ôª²¡»ìÓã¬Ë׳ƽ¥¶³ÈËÖ¢¡£Ò»µ©È·Õ»¼Õß¶àÔÚ3-5ÄêÄÚÈ¥ÊÀ£¬ÖøÃûµÄÎïÀíѧ¼Ò»ô½ð¾ÍÔøÔâÊܴ˼²²¡µÄÀ§ÈÅ¡£Ä¿Ç°¶ÔÕâÖÖ¼²²¡ÓÐЧµÄ¸ÉÔ¤ÖÎÁƵÄÑо¿Çé¿öÊÇʲôÑùµÄÄØ£¿Ð¡±à´ø´ó¼ÒÒ»¿´¾¿¾¹°É~
Ñо¿ÁÁµã
Ñо¿·¢ÏÖC9orf72ÁùºËÜÕËáÖØ¸´À©Ôö£¨HRE£©µÄË«ëÄÖØ¸´ÐòÁУ¨DpR£©¶ÔÎÞÒå½éµ¼µÄmRNA½µ½âͨ·£¨NMD£©ÓÐÒÖÖÆ×÷Óá£NMDÊÇϸ°ûÖÐÇå³ýÓк¦¡¢´íÎóRNA²úÎïµÄÒ»ÖÖ¼à²â¼°·ÀÓù»úÖÆ£¬NMDµÄÒÖÖÆ¿ÉÄÜÊÇÓÉÓÚ±í´ï¸»º¬¾«°±ËáµÄDpRµÄϸ°ûÖÐp-body£¨processing bodies£©µÄ¼õÉÙËùÖ¡£Ñо¿ÈËÔ±ÔÚϸ°ûºÍ¹ûӬģÐÍÖÐÖ¤Ã÷£¬Í¨¹ýÒÅ´«ºÍÒ©Àí·½·¨ÖØÐ¼¤»îNMDͨ·¿ÉÒÔ×è°C9orf72¸»º¬¾«°±ËáµÄDpRÓÕµ¼µÄÉñ¾¶¾ÐÔ£¬×îºóÈ·¶¨ÁËÇúÄáË¾ÌØ£¨tranilast£©ÎªNMD¼¤»îÒ©Îï¡£
Ñо¿Ë¼Â·
Ñо¿½á¹û
1. C9orf72»¼ÕßÖÐNMDµÄÒÖÖÆ
ΪÁËÆÀ¹ÀC9orf72 HRE »¼ÕßµÄNMD;¾¶ÊÇ·ñÊܵ½¸ÉÈÅ£¬½«²»Í¬C9orf72 ALSÏà¹ØÀ´Ô´µÄÒÑ·¢±íµÄת¼×éÊý¾ÝÓëÀ´×Ô¾ßÓÐNMDȱÏݵÄÈËϸ°ûµÄת¼×éÊý¾Ý½øÐÐÎÞÆ«ÉúÎïÐÅϢѧ·ÖÎö£¬·¢ÏÖÔÚC9orf72 ALSСÄÔ×éÖ¯ºÍNMDȱÏݵÄÈËϸ°ûÖ®¼ä´æÔÚ´óÁ¿ÖصþµÄ»ùÒò¡£Í¨¹ýGO·ÖÎö·¢ÏÖ£¬ÔÚÕâÐ©ÖØµþµÄ»ùÒòÖУ¬Ó¦¼¤·´Ó¦ºÍÃâÒßϵͳÏà¹Ø»ùÒòÏÔÖø¸»¼¯£¬Í¬Ê±¶Ô¸÷¸ö±È½Ï×éµÄÖØµþ»ùÒò½øÐÐÉîÈë·ÖÎö£¬·¢ÏÖNMDµ÷¿ØµÄmRNA»ýÀÛÊÇÒ»ÖÖÓëC9orf72²úÎïÌØÒìÏà¹ØµÄЧӦ¡£
ͼ1 C9orf72 ALSÓë¾ßÓÐNMDȱÏݵÄϸ°ûת¼×éÊý¾Ý·ÖÎö
2. ¸»º¬¾«°±ËáµÄC9orf72Ë«ëÄÖØ¸´ÐòÁÐÒÖÖÆNMD
Ñо¿ÈËÔ±ÀûÓùûӬģÐÍ£¬Í¨¹ýRNA-seq·ÖÎöÀ´ÆÀ¹ÀC9orf72 HRE²úÎïÔÚÌåÄÚÊÇ·ñ»áÓ°ÏìNMDµÄÕý³£±í´ï¡£×÷ÕßÑо¿ÁËHREºÍº¬ÓÐ36¸öÖØ¸´ÐòÁеĸ¬°±Ëá-¾«°±ËáË«ëÄ£¨pR36£©¶Ô¹ûÓ¬NMD»ùÒò±í´ïµÄÓ°Ïì¡£½«±í´ïHRE36»òpR36µÄ5ÈÕÁä¹ûÓ¬µÄÄÔת¼×éÊý¾ÝÓëÓÉUpF1ȱʧÒýÆðNMDͨ·ȱÏݵĹûӬת¼×éÊý¾Ý½øÐÐÁ˱ȽϷÖÎö·¢ÏÖ£¬ÕâÁ½×éÖÐÓÉÓÚNMD±»ÒÖÖÆ¶øµ¼Öµ×Îï»ùÒò»ýÀÛ£¬ÆäÖÐ36%µÄ»ùÒòÏàͬ¡£½á¹û±íÃ÷£¬C9orf72¸»º¬¾«°±ËáDpRµÄ±í´ï¿ÉÄܵ¼Ö¹ûÓ¬NMDµÄÒÖÖÆ¡£Ö®ºó£¬Ñо¿ÈËÔ±ÔÚÈËÉñ¾Ä¸Ï¸°ûÁöϸ°ûϵ£¨SH-SY5Y£©ºÍСÊóÄÔÖнøÐÐÁËÑéÖ¤¡£
ͼ2 C9orf72¸»º¬¾«°±ËáDpRµÄ±í´ïµ¼Ö¹ûÓ¬NMDµÄÒÖÖÆ
3. C9orf72Ë«ëÄÖØ¸´ÐòÁÐͨ¹ý¼õÉÙp-body·á¶È¶øÒÖÖÆNMD
Ñо¿ÈËÔ±ÓÃÃâÒßÓ«¹â±ê¼Ç¼¼Êõ¶Ôp-bodyºÍÓ¦¼¤¿ÅÁ£½øÐÐÑо¿£¬·¢ÏÖÔÚ±í´ï¸»º¬¾«°±ËáµÄDpRϸ°ûÖÐÓ¦¼¤¿ÅÁ£µÄÔö¼Ó¿ÉÄܵ¼ÖÂp-bodyµÄ¼õÉÙ£¬¼´C9orf72¸»º¬¾«°±ËáµÄDpR¿Éͨ¹ý¼õÉÙp-bodyµÄ·á¶È¶øÒÖÖÆNMD¡£
ͼ3 GFp-GR36±í´ïϸ°ûp-body¼õÉÙµ¼ÖÂNMDÒÖÖÆ
×¢£ºGR36£º¸Ê°±Ëᾫ°±Ëá36¸öÖØ¸´ÐòÁУ»GFp-GR36£º¶¾ÐÔ±Èδ¼Ó±êÇ©µÄGR36µÍ£¬µ«¶¾ÐÔÓëpR36Ï൱¡£
4. ¼¤»îNMDͨ·¿ÉÒÔ×è°Ë«ëÄÖØ¸´ÐòÁе;ÐÔ
UpF1ÊÇÆô¶¯NMDµÄ¹Ø¼üµ°°×£¬Ñо¿·¢ÏÖÔÚÈËSH-SY5Yϸ°ûÖÐUpF1µÄ±í´ï¿ÉÒÔÓÐЧµØ·ÀÖ¹HRE36ÒýÆðµÄϸ°ûµòÍö£»ÔÚ¹ûӬģÐÍÖÐUpF1ÄÜÄæ×ª4ÖÖNMDµ×ÎïµÄ»ýÀÛ£¬²¢ÄÜÓÐЧµØÍì¾ÈpR36ÒýÆðµÄÔ˶¯Éñ¾ÔªºÍÖáͻͶÉäµÄ¶ªÊ§¡£Í¨¹ýÔÚÈ˺͹ûӬʵÑéÖеÄÑо¿±íÃ÷£¬Í¨¹ýÔö¼ÓNMDͨ·ÖкËÐĵ°°×µÄ±í´ï¿É»Ö¸´NMDµÄ»îÐÔ£¬´Ó¶ø×è°¸»º¬¾«°±ËáµÄDpRÒýÆðµÄÉñ¾¶¾ÐÔ¡£
ͼ4 UpF1ÍêÈ«×è¶ÏGFp-GR36¶ÔSH-SY5Yϸ°ûµÄ¶¾ÐÔ×÷ÓÃ
´ËÍ⣬Ñо¿ÈËÔ±Ñо¿ÁËËÄÖÖ»¯ºÏÎtranilast, nifulumic acid, febuxostat and nitazoxanide£©£¬ÔÚÈËSH-SY5Yϸ°ûÖУ¬Ñо¿·¢ÏÖÇúÄáË¾ÌØ¿ÉÓÐЧµØÖØÐ¼¤»îNMD»îÐÔ£¬ÓÐЧµØÒÖÖÆGFp-GR36»òHRE36ÓÕµ¼µÄϸ°ûµòÍö¡£ÔÚ¹ûӬʵÑéÖУ¬¾ÇúÄáË¾ÌØ´¦Àíºó£¬¹ûÓ¬Ó¼ÊýÏÔÖøÔö¼Ó£¬³ÉÌå´æ»îÂʺÍÔ˶¯¹¦ÄÜÏÔÖøÔöÇ¿¡£Òò´Ë£¬ÇúÄáË¾ÌØ¿É½â³ýC9orf72 DpR¶ÔÈËϸ°ûºÍ¹ûÓ¬µÄÉñ¾¶¾ÐÔ¡£
½áÂÛ
¸ÃÏîÑо¿½ÒʾÁ˵¼Ö¼¡Î®ËõÐÔ²àË÷Ó²»¯Ö¢µÄлúÖÆ£¬Ö¤ÊµÁ˼¤»îÎÞÒå½éµ¼µÄmRNA½µ½âͨ·¿ÉÒÔ×÷ΪÖÎÁÆALSµÄвßÂÔ£¬·¢ÏÖÁËÒ»ÖÖÏÖÓÃÓÚÖÎÁÆÏø´µÄÒ©ÎïÓпÉÄܳÉΪÖÎÁÆALSµÄÐÂÒ©¡£
ÎÄÕÂ¿ÆÆÕ
ÎÞÒå½éµ¼µÄmRNA½µ½âͨ·£¨nonsense-mediated mRNA decay£¬NMD£©£ºÒ»Öֹ㷺´æÔÚÓÚÕæºËϸ°ûÖеÄmRNAÖÊÁ¿¼à¿Ø»úÖÆ£¬¸Ã»úÖÆÄÜʶ±ð²¢½µ½âº¬ÓÐÌáǰÖÕÖ¹ÃÜÂë×ÓµÄת¼²úÎïÒÔ·ÀÖ¹¶¾ÐÔµ°°×µÄ²úÉú¡£ C9orf72»ùÒòÍ»±ä£ºµ¼Ö¼¡Î®Ëõ²àË÷Ó²»¯Ö¢µÄ×îÖ÷ÒªµÄÍ»±äÐÎʽ£¬¸ÃÍ»±äÓÉGGGGCC³¤Öظ´ÐòÁвåÈëC9orf72»ùÒòµÄÄÚº¬×ÓÖÐÔì³É¡£ HRE£¨hexanucleotide repeat expansion£©£ºÁùºËÜÕËáÖØ¸´À©Ôö£¨GGGGCC£©¡£ DpR£¨dipeptide repeat£©£ºË«ëÄÖØ¸´ÐòÁС£ p-body£¨processing bodies£©£ºNMD»úÖÆÖеĹؼü³É·Ö£¬ËüÊÇÒ»ÖÖÎÞĤµÄºËÌǺ˵°°×¿ÅÁ££¬¸»º¬µ°°×ÖÊ£¬²ÎÓëRNAµÄ½µ½â¡£ ÇúÄáË¾ÌØ£¨tranilast£©£º¿¹±ä̬·´Ó¦Ò©£¬¿ÉÓÃÓÚÖ§Æø¹ÜÏø´¼°¹ýÃôÐÔ±ÇÑ×µÄÔ¤·ÀÐÔÖÎÁÆ¡£ UpF1£ºNMDͨ·¼¤»îËù±ØÐèµÄ±£ÊصĻù±¾µ÷¿Øµ°°×£¬¿É´Ù½øºËËáÄÚÇÐøºÍºËËáÍâÇÐø¶ÔmRNAµÄÇи Ó¦¼¤¿ÅÁ££¨stress granules£©£ºÒ»ÖÖºËÌǺ˵°°×¿ÅÁ££¬ÔÚÓ¦¶Ôϸ°ûÄÚ»·¾³±ä»¯Ê±Æð×ÅÖØÒªµÄ×÷ÓᣠpR36£¨proline-arginine dipeptide with 36 repeats£©£º¸¬°±Ëá-¾«°±ËáË«ëÄ36¸öÖØ¸´ÐòÁС£ GR36£¨glycine-arginine dipeptide with 36 repeats£©£º¸Ê°±Ëá-¾«°±ËáË«ëÄ36¸öÖØ¸´ÐòÁС£ GFp-GR36£ºÓÃGFp£¨ÂÌɫө¹âµ°°×£©±ê¼ÇµÄGR36£¬ËüµÄ¶¾ÐÔ±Èδ±ê¼ÇµÄGR36µÍ£¬µ«¶¾ÐÔÓëpR36Ï൱¡£°²Åµ»ùÒòÔÚת¼×é²âÐò·½ÃæÓµÓжàÑù»¯µÄ²úÆ·ÀàÐÍ£¬º¸ÇÁËÆÕͨת¼×é²âÐò²úÆ·¡¢Ò½Ñ§×ªÂ¼×é²âÐò²úÆ·¡¢lncRNA²âÐò²úÆ·¡¢Ò½Ñ§lncRNA²âÐò²úÆ·¡¢circRNA²âÐò²úÆ·¡¢È«×ªÂ¼×é²âÐò²úÆ·µÈ£¬¸÷ÀàÐͲúÆ·¾ù¾ßÓзḻµÄÏîÄ¿¾Ñé¼°ÎïÖÖ¾Ñ飬ӵÓÐרҵµÄʵÑéÍŶӡ¢·ÖÎöÍŶÓÒÔ¼°ÁìÏȵĶþ´ú¡¢Èý´ú²âÐòƽ̨£¬Îª´ó¼ÒÌṩ¸ßÖÊÁ¿µÄ²âÐò·þÎñ£¬Âú×ã¹ã´ó¿ÆÑй¤×÷ÕßÃǵÄÑо¿ÐèÇó£¬Ò»ÇÐֻΪÖúÁ¦¿ÆÑС£
²Î¿¼ÎÄÏ×
Xu Wangchao, Bao puhua, Jiang Xin, et al. Reactivation of nonsense-mediated mRNA decay protects against C9orf72 dipeptide-repeat neurotoxicity[J]. Brain, 2019, 142: 1349-1364.